Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses

Key Points Treatment with IFNα was associated with distinct molecular responses in patients with JAK2-mutated MPN compared with CALR-mutated MPN. Among patients treated with IFNα who did not achieve CHR, DNMT3A mutations emerged more frequently than non-DNMT3A mutations.

[1]  F. Camargo,et al.  Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms , 2021, Cell stem cell.

[2]  P. Campbell,et al.  Phylogenetic reconstruction of myeloproliferative neoplasm reveals very early origins and lifelong evolution , 2020, bioRxiv.

[3]  K. Krejcy,et al.  Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension , 2020 .

[4]  R. Skoda,et al.  Loss of Dnmt3a Confers Resistance to Pegifnα in JAK2-V617F Mouse Model , 2020 .

[5]  K. Krejcy,et al.  Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups , 2020, HemaSphere.

[6]  V. Skov.  Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses , 2020, Cancers.

[7]  D. Steensma,et al.  What To Tell Your Patient With Clonal Hematopoiesis And Why: Insights From Two Specialized Clinics. , 2020, Blood.

[8]  J. González-Martín,et al.  Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A/TET2/ASXL1 Mutations , 2020, Cancers.

[9]  K. Krejcy,et al.  Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. , 2020, The Lancet. Haematology.

[10]  J. Ottesen,et al.  Data‐driven analysis of JAK2V617F kinetics during interferon‐alpha2 treatment of patients with polycythemia vera and related neoplasms , 2020, Cancer medicine.

[11]  P. Guglielmelli,et al.  Mutation‐enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera , 2020, British journal of haematology.

[12]  R. Kralovics,et al.  Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions , 2019, International Journal of Hematology.

[13]  A. Mullally,et al.  The Molecular Genetics of Myeloproliferative Neoplasms. , 2019, Cold Spring Harbor perspectives in medicine.

[14]  H. Hasselbalch,et al.  Prevalence and phenotypes of JAK2 V617F and Calreticulin mutations in a Danish general population. , 2019, Blood.

[15]  L. Bullinger,et al.  Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation. , 2018, Blood.

[16]  R. Skoda.  Accelerating myelofibrosis through loss of Dnmt3a. , 2018, Blood.

[17]  E. Solary,et al.  Differential Impact of Interferon Alpha on JAK2V617F and Calr Mutated Hematopoietic Stem and Progenitor Cells in Classical MPN , 2018, Blood.

[18]  A. Mead,et al.  Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET) , 2018, Blood.

[19]  P. A. Futreal,et al.  PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy , 2018, Cell stem cell.

[20]  T. Brümmendorf,et al.  JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation , 2018, Leukemia.

[21]  P. Campbell,et al.  Classification and Personalized Prognosis in Myeloproliferative Neoplasms , 2018, The New England journal of medicine.

[22]  S. Carr,et al.  PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. , 2018, Blood.

[23]  S. Mccarroll,et al.  Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms , 2018, Science Translational Medicine.

[24]  Š. Pospíšilová,et al.  Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status , 2017, Leukemia.

[25]  S. Gabriel,et al.  Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease , 2017, The New England journal of medicine.

[26]  A. Mead,et al.  Myeloproliferative neoplasm stem cells. , 2017, Blood.

[27]  M. Konopleva,et al.  Efficacy and safety of pegylated interferon alpha-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV): results of a phase 2 study after a 7-year median follow-up , 2017, The Lancet. Haematology.

[28]  D. Neuberg,et al.  Prognostic Mutations in Myelodysplastic Syndrome after Stem‐Cell Transplantation , 2017, The New England journal of medicine.

[29]  A. LaCasce,et al.  Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Tefferi,et al.  Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients , 2016, Blood Cancer Journal.

[31]  P. Guglielmelli,et al.  Targeted deep sequencing in polycythemia vera and essential thrombocythemia. , 2016, Blood advances.

[32]  H. Hasselbalch,et al.  Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment , 2016, PloS one.

[33]  T. Druley,et al.  Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults , 2016, Nature Communications.

[34]  B. Bellosillo,et al.  Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing , 2016, Blood Cancer Journal.

[35]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[36]  P. Beer.  Molecular genetics of the myeloproliferative neoplasms , 2016 .

[37]  T. Brümmendorf,et al.  Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry , 2016, Journal of Hematology & Oncology.

[38]  H. Hasselbalch,et al.  Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera , 2016, Leukemia & lymphoma.

[39]  S. Carillo,et al.  Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations. , 2015, Blood.

[40]  M. Cazzola,et al.  Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. , 2015, Blood.

[41]  Peter J Campbell,et al.  DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype , 2015, Haematologica.

[42]  L. Möllgård,et al.  Characterization and prognostic features of secondary acute myeloid leukemia in a population‐based setting: A report from the Swedish Acute Leukemia Registry , 2015, American journal of hematology.

[43]  Paola Guglielmelli,et al.  Effect of mutation order on myeloproliferative neoplasms. , 2015, The New England journal of medicine.

[44]  Christian Beisel,et al.  Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. , 2014, Blood.

[45]  M. Cazzola,et al.  Mutations and prognosis in primary myelofibrosis , 2013, Leukemia.

[46]  H. Vestergaard,et al.  Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. , 2013, Leukemia research.

[47]  O. Abdel-Wahab,et al.  Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. , 2013, Blood.

[48]  T. Barbui,et al.  Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. , 2013, Blood.

[49]  P. Dickman,et al.  Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  J. Melo,et al.  Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patient , 2012, British journal of haematology.

[51]  T. Barbui,et al.  Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia , 2010, Haematologica.

[52]  M. Møller,et al.  Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission , 2009, Hematology.

[53]  M. Konopleva,et al.  Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  D. Margaritis,et al.  Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients , 2009, Annals of Hematology.

[55]  M. Møller,et al.  Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden , 2008, Hematology.

[56]  S. Chevret,et al.  Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. , 2008, Blood.

[57]  M. Møller,et al.  Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera , 2008, Annals of Hematology.

[58]  N. Shinton.  WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[59]  M. Stratton,et al.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. , 2007, The New England journal of medicine.

[60]  G. Massonnet,et al.  High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. , 2006, Blood.

[61]  M. Griesshammer,et al.  Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). , 2005, Blood.

[62]  J. D. van der Walt,et al.  Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. , 2005, The New England journal of medicine.

[63]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[64]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[65]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[66]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[67]  T. Barbui,et al.  Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. , 1995, The New England journal of medicine.

[68]  R. Silver.  RECOMBINANT INTERFERON-ALPHA FOR TREATMENT OF POLYCYTHAEMIA VERA , 1988, The Lancet.

[69]  M. Cazzola,et al.  The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients , 2014, Leukemia.

[70]  O. Linder,et al.  A phase II trial of pegylated interferon α‐2b therapy for polycythemia vera and essential thrombocythemia , 2006 .

[71]  L. Wasserman,et al.  From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. , 1997, Seminars in hematology.

[72]  W. Dameshek.  Some speculations on the myeloproliferative syndromes. , 1951, Blood.